Director sold ~$851K of Immunitybio
Scheduled in advanceLoading…
IBRX · NASDAQ · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in San Diego, Ca.
In the last 90 days, no insider of Immunitybio reported an open-market purchase and 2 open-market sales worth about $1.12M. Every figure links to its official SEC, House, Senate or USAspending record.
Revenue
$51.2M
+93.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$288M
This quarter −$70M, a year earlier −$80.8M
Net debt
—
Debt —, cash $75.7M, at Jun 30, 2026
Net income, last 12 months
−$992M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$1.12M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Director sold ~$851K of Immunitybio
Scheduled in advanceDirector sold ~$269K of Immunitybio
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
2 active phase 3 trials and 14 active phase 2 trials led by this company, mostly in long covid, sepsis, bladder cancer. The ones with the nearest registered primary completion date still ahead:
3 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.